Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of topical omiganan for mild to moderate facial seborrheic dermatitis
NL-OMON48780Phase 2Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Sep 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of omiganan in seborrheic dermatitis (SD) (3 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Skin microbiome and mycobiome, Gut microbiome and 16 more. Started Sep 2018; status: completed.
02
Drugs
omiganan
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on NL-OMON48780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48780.